2024 年第 6 期 第 0 卷

新型抗嗜酸性粒细胞药物在哮喘中应用的研究进展

Research progress of new anti-eosinophilic drugs in asthma

作者：褚小娟1杨文婷1唐连涛2李向魁3付臣昆1田鑫1程义局1，4

英文作者：Chu Xiaojuan1 Yang Wenting1 Tang Liantao2 Li Xiangkui3 Fu Chenkun1 Tian Xin1 Cheng Yiju14

单位：1贵州医科大学附属医院呼吸与危重症医学科，贵阳550004；2贵州医科大学附属医院内科，贵阳550004；3贵州医科大学附属公共卫生救治中心呼吸与危重症医学科，贵阳550004；4贵州省贵阳市第四人民医院呼吸与危重症医学科，贵阳550004

英文单位：1Department of Pulmonary and Critical Care Medicine the Affiliated Hospital of Guizhou Medical University Guiyang 550004 China; 2Department of Internal Medicine the Affiliated Hospital of Guizhou Medical University Guiyang 550004 China; 3Department of Pulmonary and Critical Care Medicine Guizhou Medical University Affiliated Public Health Treatment Center Guiyang 550004 China; 4Department of Pulmonary and Critical Care Medicine the Fourth People′s Hospital of Guiyang Guizhou Province Guiyang 550004 China

关键词：哮喘；抗嗜酸性粒细胞药物；嗜酸性粒细胞性气道炎症

英文关键词：Asthma;Anti-eosinophildrugs;Eosinophilicairwayinflammation

• 摘要：

• 哮喘是当今世界上常见的慢性非传染性疾病之一，其特征是可变的气体阻塞，引起呼吸困难和喘息。嗜酸性粒细胞性气道炎症通常被视为慢性气道病变最具影响力的可诊断特点。在过去的十几年里，已研制了多种针对这种特征的单克隆抗体，主要包括抗白细胞介素5（IL-5）或IL-5受体α（美泊利珠单抗、瑞利珠单抗和贝那利珠单抗）、IL-13（来瑞组单抗和曲罗芦单抗）、IL-4受体α（度普利尤单抗）、免疫球蛋白E（奥马珠单抗）和抗胸腺基质淋巴生成素（特泽鲁单抗）的单克隆抗体。本文从哮喘的发病机制、新型抗嗜酸性粒细胞药物在哮喘治疗中的进展等方面进行综述。

• Asthma is one of the common chronic non-communicable diseases in the world today, which is characterized by variable gas obstruction, causing dyspnea and wheezing. Eosinophilic airway inflammation is often considered to be the most influential diagnosable feature of chronic airway disease. Over the past decade, multiple monoclonal antibodies have been developed targeting this characteristic. Mainly including anti interleukin-5 (IL-5) or IL-5 receptors α (mepolizumab, razumab, and benazizumab), IL-13 (lebrikizumab and tralokinumab), IL-4 receptor α (monoclonal antibodies against dupilumab), immunoglobulin E (omalizumab), and thymic stromal resistance lymphatic hormone (tezepelumab) of monoclonal antibodies. This article reviews the pathogenesis of asthma and the progress of new anti-eosinophil drugs in the treatment of asthma.